Evidence map›Paper›PMID 31625720›Full record

ReviewChemical research in toxicology2020

Use of Zebrafish in Drug Discovery Toxicology.

Steven Cassar, Isaac Adatto, Jennifer L Freeman, Joshua T Gamse, Iñaki Iturria, Christian Lawrence, Arantza Muriana, Randall T Peterson, Steven Van Cruchten, Leonard I Zon

Abstract readReview
In one paragraph

Review in Chemical research in toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 247 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
247citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

247 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Toxicity of the Covalent Organic Framework Material TpPa to Zebrafish.Animals : an open access journal from MDPI · 2026
    Article
  15. Cystic fibrosis: insights from zebrafish models.Disease models & mechanisms · 2026
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

187 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Steven CassarPreclinical Safety , AbbVie , North Chicago , Illinois 60064 , United States.ORCID 0000-0002-9409-6714
Isaac AdattoStem Cell and Regenerative Biology , Harvard University , Cambridge , Massachusetts 02138 , United States.
Jennifer L FreemanSchool of Health Sciences , Purdue University , West Lafayette , Indiana 47907 , United States.
Joshua T GamseDrug Safety Evaluation , Bristol-Myers Squibb , New Brunswick , New Jersey 08901 , United States.
Iñaki IturriaBiobide , San Sebastián , Spain 20009.
Christian LawrenceAquatic Resources Program , Boston Children's Hospital , Boston , Massachusetts 02115 , United States.
Arantza MurianaBiobide , San Sebastián , Spain 20009.
Randall T PetersonPharmacology and Toxicology, College of Pharmacy , University of Utah , Salt Lake City , Utah 84112 , United States.
Steven Van CruchtenUniversity of Antwerp , Wilrijk 2610 , Belgium.ORCID 0000-0002-3144-1840
Leonard I ZonStem Cell Program and Division of Hematology/Oncology, Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Harvard Stem Cell Institute, Stem Cell and Regenerative Biology Department , Harvard University , Boston , Massachusetts 02138 , United States.

Funding

TRANSCRIPTION FACTOR GATA-1 IN TERMINAL ERYTHROID DEVELOPMENTP01HL032262 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ORKIN, STUART H · 1985 to 2021
$38.9M
Transcriptional and epigenetic heterogeneity of stem/progenitor cellsP01HL131477 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Jason Daniel Buenrostro · 2017 to 2026
$24.6M
CORE--ZEBRAFISHP30DK049216 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ZHOU, YI · 1999 to 2015
$14.3M
Cancer Biology in the ZebrafishR01CA103846 · NCI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 2003 to 2022
$7.5M
Project-002U54DK110805 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI ORKIN, STUART H, ZON, LEONARD IRA · 2016 to 2020
$5.9M
Transcriptional response to signaling during hematopoiesisR01HL144780 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI ZON, LEONARD IRA · 2019 to 2022
$2.1M
NCI NIH HHS R01 CA103846NHLBI NIH HHS P01 HL032262NHLBI NIH HHS P01 HL131477NHLBI NIH HHS R01 HL144780NIDDK NIH HHS P30 DK049216NIDDK NIH HHS U54 DK110805
6 · The paper itself

Abstract

Unpredicted human safety events in clinical trials for new drugs are costly in terms of human health and money. The drug discovery industry attempts to minimize those events with diligent preclinical safety testing. Current standard practices are good at preventing toxic compounds from being tested in the clinic; however, false negative preclinical toxicity results are still a reality. Continual improvement must be pursued in the preclinical realm. Higher-quality therapies can be brought forward with more information about potential toxicities and associated mechanisms. The zebrafish model is a bridge between in vitro assays and mammalian in vivo studies. This model is powerful in its breadth of application and tractability for research. In the past two decades, our understanding of disease biology and drug toxicity has grown significantly owing to thousands of studies on this tiny vertebrate. This Review summarizes challenges and strengths of the model, discusses the 3Rs value that it can deliver, highlights translatable and untranslatable biology, and brings together reports from recent studies with zebrafish focusing on new drug discovery toxicology.

Indexed as

Drug DiscoveryModels, AnimalZebrafishAnimalsAnimal Use AlternativesDrug-Related Side Effects and Adverse ReactionsEmbryo, NonmammalianToxicity Tests

Identifiers

PMID31625720
PMCPMC7162671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.